Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | DRD1 | P21728 | 3/20 | 0.42 |
| ▸ | DRD5 | P21918 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30134456 | 1.00 | MPO (0.42) | MPODRD2DRD3DRD1DRD5 | |
| Acetonitrile SCHEMBL28416409 | 0.92 | MPO (0.38) | MPODRD2DRD3DRD1DRD5 | |
| SCHEMBL1479378 | 0.85 | MAOA (0.50) | MPODRD2DRD3DRD1DRD5 | |
| SCHEMBL27861257 | 0.83 | CYP1A2 (0.43) | MPOCYP11B2BCL2MAOAMAOB | |
| SCHEMBL1616390 | 0.81 | CA2 (0.47) | MPODRD2DRD3DRD1DRD5 | |
| SCHEMBL326339 | 0.81 | DRD2 (0.41) | DRD2DRD3DRD1DRD5CYP11B2 | |
| SCHEMBL21860163 | 0.81 | NQO1 (0.42) | CA5A | |
| SCHEMBL9115695 | 0.79 | MTNR1A (0.35) | CA2CA5A | |
| Acetonitrile SCHEMBL29194900 | 0.78 | MAOA (0.44) | MPODRD2DRD3DRD1DRD5 | |
| SCHEMBL9113494 | 0.78 | CA2 (0.46) | CA2CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087655-A1 | 6-Substituted indanoyl amino acid conjugates as mimics to the biological activity of coronatine | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV (DE) | 2004-05-06 | — | — | US | claimed |
| EP-1351922-A2 | 6-SUBSTITUTED INDANOYL AMINO ACID CONJUGATES AS MIMICS TO THE BIOLOGICAL ACTIVITY OF CORONATINE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002055480-A2 | 6-SUBSTITUTED INDANOYL AMINO ACID CONJUGATES AS MIMICS TO THE BIOLOGICAL ACTIVITY OF CORONATINE | MAX PLANCK GESELLSCHAFT (DE) | 2002-07-18 | — | — | WO | claimed |
| WO-1995016215-A1 | NOVEL SUBSTITUTED NAPHTHOPYRANS | PPG INDUSTRIES, INC. (US) | 1995-06-15 | — | — | WO | claimed |
| CN-115925530-A | 3,4-dihydronaphthalene-1 (2H) -ketone compound, preparation method and application | 滨州医学院 | 2023-04-07 | — | — | CN | disclosed |
| US-8680270-B2 | Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2086546-B1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-7915295-B2 | Viricides; HIV antivirals effective against problematic drug escape mutants; N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-7915295-B2 | Viricides; HIV antivirals effective against problematic drug escape mutants; N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-7915295-B2 | Viricides; HIV antivirals effective against problematic drug escape mutants; N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-20100317712-A1 | Estrogen Agonists/Antagonists For Preventing Breast Cancer | CAMERON KIMBERLY O | 2010-12-16 | — | — | US | disclosed |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-1996021656-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| WO-1995016215-A1 | NOVEL SUBSTITUTED NAPHTHOPYRANS | PPG INDUSTRIES, INC. (US) | 1995-06-15 | — | — | WO | disclosed |
| EP-0260555-B1 | BENZO-FUSED CYCLOALKANE AND OXA- AND THIA-, CYCLOALKANE TRANS-1,2-DIAMINE DERIVATIVES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-04-22 | — | — | EP | disclosed |
| US-5043350-A | Analgesics, diuretics | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-08-27 | — | — | US | disclosed |
| US-5010085-A | Analgesis and/or diuretics | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-04-23 | — | — | US | disclosed |
| US-4929627-A | ANALGESICS, DIURETICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-05-29 | — | — | US | disclosed |
| US-4876269-A | ANALGESICS, DIURETICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
| EP-0260555-A1 | Benzo-fused cycloalkane and oxa- and thia-, cycloalkane trans-1,2-diamine derivatives | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317712-A1 | Estrogen Agonists/Antagonists For Preventing Breast Cancer | ESR1, GPER1, ESR2 | MPO 3748/4885DRD2 2972/4885DRD3 3085/4885 |
| US-20040087655-A1 | 6-Substituted indanoyl amino acid conjugates as mimics to the biological activity of coronatine | CORO1C, CORO1A, AGER | MPO 2499/4885DRD2 3606/4885DRD3 4038/4885 |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | MPO 94/4885DRD2 4655/4885DRD3 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.